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For cancer patients with chronic hepatitis B virus (HBV) infection, who receive cytotoxic chemotherapy, HBV reactivation is a well-
described complication, which may result in varying degrees of liver damage. Several clinical features and the pre-chemotherapy HBV
viral load have been suggested to be associated with an increased risk of developing the condition: (1) to assess the clinical and
virological factors in a comprehensive manner and thereby identify those that are associated with the development of HBV
reactivation; (2) to develop a predictive model to quantify the risk of HBV reactivation. In all, 138 consecutive cancer patients who
were HBV carriers and undergoing chemotherapy were studied, of which 128 patients had sera available for real-time PCR HBV
DNA measurement. They were followed up throughout their course of chemotherapy and the HBV reactivation rate was
determined. The clinical and virological features between those who did and did not develop viral reactivation were compared. These
included age, sex, baseline liver function tests, HBeAg status and viral load (HBV DNA) prior to the chemotherapy, and the use of
specific cytotoxic agents. In all, 36 (26%) developed HBV reactivation. Multivariate analysis revealed pre-chemotherapy HBV DNA
level, the use of steroids and a diagnosis of lymphoma or breast cancer to be significant factors. Based on real-time HBV DNA PCR
assay, detectable baseline HBV DNA prior to the administration of cytotoxic chemotherapy, the use of steroids and a diagnosis of
lymphoma or breast cancer are predictive factors for the development of HBV reactivation. A predictive model was developed from
the current data, based on a logistic regression method.
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For cancer patients who have chronic hepatitis B virus (HBV)
infection, there is a high rate of hepatic complications during
cytotoxic chemotherapy, and this has mainly been attributable to
HBV reactivation. The condition is manifested with abnormal liver
function tests that show a hepatitic picture, and it is confirmed by
raised levels of serum HBV DNA. The clinical spectrum ranges
from asymptomatic hepatitis to fatal hepatic failure (Galbraith et al,
1975; Hoofnagle et al, 1982; Lok et al, 1991; Nokamura et al, 1996;
Kumagai et al, 1997; Markovic et al, 1999; Yeo et al, 2000a).
However, even in its mildest form with spontaneous recovery, a
patient’s prognosis from cancer may still be impaired from the
disruption in chemotherapeutic administration with treatment
delay, or premature termination of the anticancer therapy. The
incidence of HBV reactivation in hepatitis B surface antigen
(HBsAg) seropositive cancer patients undergoing cytotoxic che-
motherapy has been reported to be 20% or higher (Lok et al, 1991;
Nokamura et al, 1996; Kumagai et al, 1997; Markovic et al, 1999;
Yeo et al, 2000a). No preventive measures have been proven to
prevent or reduce the incidence of HBV reactivation, although
more recent reports have suggested that the prophylactic use of the
antiviral agent lamivudine, prior to the start of chemotherapy, may
reduce the occurrence of the condition (Rossi et al., 2001; Liao et al,
2002; Lim et al, 2002; Persico et al, 2002; Shibolet et al, 2002; Yeo
et al, 2002). There has also been concern about the emergence of
viral mutant as a result of lamivudine therapy, and, to date, limited
data are available on the clinical impact of these mutants in
immunosuppressed subjects. Limiting the use of the prophylactic
antiviral to patients who are at the highest risk of developing viral
reactivation may reduce the potential complication of mutant
emergence, and at the same time be more cost-effective.
Despite the wide recognition of HBV reactivation, there is still
no consensus as to the associated risk factors. Clinical features
such as young age, male sex, the diagnosis of lymphoma and the
use of anthracyclines and/or steroids as part of the anticancer
therapy have been suggested (Lok et al, 1991; Yeo et al, 2000a),
while virological factors such as HBeAg positivity (Yeo et al,
2000a,b) and, more recently, the pre-chemotherapy HBV viral load
(Lau et al, 2002) have also been associated.
The objectives of this study were: (1) to assess the clinical and
virological factors in a comprehensive manner in order to identify
those that are associated with the development of HBV reactiva-
tion; and (2) to develop a predictive model to identify patients
more likely to develop HBV reactivation.
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lPATIENTS AND METHODS
In all, 138 consecutive cancer patients who were chronic HBV
carriers and planned for cytotoxic chemotherapy were consented
and followed up throughout their course of treatment. The study
was approved by the Clinical Research Ethics Committee of the
Chinese University of Hong Kong.
Investigations
Prior to study entry, the following investigations were undertaken
in all patients: hepatitis B s-antigen (HBsAg), hepatitis B e-antigen/
antibody (HBeAg/anti-HBe) HBV DNA level (measured by
commercially available Quantiplex HBV DNA assay (bDNA),
Chiron, USA), complete blood picture (CBP, which included
haemoglobin, red cell count, mean cell volume, white cell count
and differential and platelet count), renal function tests (RFT,
which included sodium, potassium, urea, creatinine and creatinine
clearance), liver function test (LFT, which included total protein,
albumin, total bilirubin, alanine transaminase, alkaline phospha-
tase) and clotting profile. In addition, one 3-ml serum sample was
collected for later retrospective analysis of HBV DNA by a real-
time PCR assay (Zhong et al, in press).
During the course of chemotherapy, on days 1 and 10 of each
cycle, CBP, clotting profile, RFT and LFT were monitored together
with clinical signs and symptoms. Monitoring of these parameters
was continued for 8 weeks after completion of chemotherapy.
When a patient was found to have developed hepatitis (as
defined below) during the course of chemotherapy, HBV DNA was
performed (measured by Quantiplex bDNA assay), with immu-
noglobulin M (IgM) antibody to hepatitis A virus (IgM anti-HAV),
HCV RNA, anti-HDV, ANA and other investigations as clinically
indicated.
Hepatitis serology
Hepatitis A, B and D markers were detected by commercial
enzyme immunoassays (Cobas Core Anti-HAV IgM EIA, Roche
Diagnostics GmbH, Deutschland; Auszyme MC Dynamic (HBsAg),
Abbott Laboratories, USA; Cobas Core Anti-HBc IgM EIA, Roche
Diagnostics GmbH, Deutschland; MONOLISA HBe, Sanofi Diag-
nostics Pasteur, USA; Abbott Anti-Delta EIA, Abbott Laboratories,
USA). HCV RNA was detected by reverse transcription polymerase
chain reaction using primers 209, 211, 939 and 940 as previously
described (Chan et al, 1992).
For routine use including establishment of the diagnosis of HBV
reactivation, HBV DNA level was measured by using the branched
DNA hybridisation assay (Quantiplex HBV DNA assay (bDNA),
Chiron, USA), which has a lower detection limit of 0.7 10
6
genome equivalentml
 1.
Real-time HBV DNA PCR assay
For the purpose of assessing the impact of viral load on HBV
reactivation, we used the real-time PCR to quantify serum HBV
DNA, which has a lower detection limit for HBV DNA of
2.9 10
3g.e.ml
 1 (Zhong et al, in press). In total, 128 patients
had sera available for real-time PCR analysis and these were tested
in a single batch. Their serum samples were separated as soon as
the blood was coagulated and stored at  801C in RNase-free tubes.
Isolation of nucleic acids was performed using the High Pure Viral
Nucleic Acid Kit (Roche, Mannheim, Germany). For each isolation,
200ml of serum was used resulting in 50ml of nucleic acid extract.
For HBV DNA quantification by real-time PCR, PCR amplification
was performed with PCR primers located at regions that are
universally conserved among the six HBV genotypes (A–F)
corresponding to the HBV X gene. The oligonucleotide sequences
of primers were: txs3 (1434–154), TCT CAT CTG CCG GAC CGT
GT; xas1 (1668–148), AAT TTA TGC CTA CAG CCT CC. A volume
of 5ml equivalent of serum was used for real-time amplification in
a final 10ml reaction volume, using 1 Fast Start SYBR Green I
Master Mix (Roche), MgCl2 (4mM) and 0.3mM concentration of
each primer. The amplification procedure, utilising the LightCycler
instrument (Roche), was as follows: 951C for 10min, followed by
45 cycles of 951C for 15s, 571C for 10s and 721C for 12s, followed
by denaturation of amplification samples by slow increase of
temperature (0.11Cs
 1)u pt o9 5 1C.
Definition of HBV reactivation
The following definitions, based on a definition of Lok et al (1991),
and subsequently modified by us (Yeo et al, 2000a), were applied.
‘Hepatitis’ was defined as a threefold or greater increase in serum
ALT level that exceeded the reference range (458iul
 1)o ra n
absolute increase of ALT to over 100iul
 1. ‘HBV reactivation’ was
defined as either one of the following: using the Quantiplex b DNA
assay, Chiron assay, an increase in HBV DNA levels of 10-fold or
greater when compared with the baseline level, or an absolute
increase of HBV DNA level that exceeded 1000 10
6g.e.ml
 1
during chemotherapy, in the absence of clinical or laboratory
features of acute infection with hepatitis A, C and delta virus or
other systemic infections.
Comprehensive assessment of the clinical and virological
factors in association with the development of HBV
reactivation
Among the 128 patients who had sera available for the real-time
PCR analysis for HBV DNA, the following factors were compared
between those who did and those who did not develop viral
reactivation: age, sex, tumour type, use of steroids, anthracyclines
and 5-fluorouracil, pre-chemotherapy liver functions (albumin,
total bilirubin and alanine transaminase), HBeAg status, HBV
DNA using real-time PCR measurement.
Statistical methods
Univariate analysis for detecting significant prognostic factors for
HBV reactivation was done using w
2 test or Fisher’s exact test.
Prognostic factors for HBV reactivation were then determined by
multivariate analysis using a stepwise logistic regression model
based on a backward elimination procedure for model selection,
with a significance level of o0.1 for a factor to enter into the
logistic model; the same significance level was used to retain
variables in the final model. A predictive model was obtained using
the parameters of the final logistic model. The classification to the
HBV reactivation group was based on the probability estimate
from the logistic model, where an optimal cutoff point was
determined using the ROC curve technique; the ROC curve refers
to the receiver operating characteristic curve, which is a plot of the
true-positive rate vs false-positive rate associated with the
classification rules for all possible choices of critical values
(Hanley, 1989).
RESULTS
In all, 36 patients were determined to have developed HBV
reactivation (the ‘reactivation’ group) and 92 patients were
determined not to have HBV reactivation (the ‘non-reactivation’
group) (Table 1).
There were 56 males and 72 females; 16 (28.6%) males and 20
(27.8%) females developed HBV reactivation (P¼1.000). Between
the ‘reactivation’ and the ‘non-reactivation’ groups, the median
ages were 46.5 and 49.0 years, respectively (P¼0.265). There
were 39 patients with breast cancer, 29 with gastrointestinal
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lmalignancies, 17 head and neck cancers, 13 lung cancers, 12 non-
Hodgkin’s lymphoma and 18 other malignancies. Among these
patients, 16 who had breast cancers (41.0% of the patients with this
tumour type, P¼0.053), seven non-Hodgkin’s lymphoma (58.3%,
P¼0.037), two gastrointestinal malignancies (6.9%, P¼0.0041),
five head and neck (29.4%, P¼1.000), three lung cancers (23.1%,
P¼1.000) and three (16.6%, P¼0.396) with other malignancies
developed viral reactivation.
Of the 128 patients, 15 were HBeAg positive, of which four
(26.7%) developed reactivation, while 32 of the 113 (28.3%)
patients who were HBeAg negative/anti-HBe positive developed
the condition (P¼1.000). Using the real-time PCR assay, 82
patients were detected to have HBV DNA, 31 (37.8%) of whom
developed reactivation; in contrast, only five of the 41 (10.9%)
patients who had undetectable HBV DNA developed the condition
(P¼0.001).
There was no statistically significant difference in baseline liver
function in terms of ALT, bilirubin and albumin between the two
groups of patients. Out of 56 patients, 22 (39%) received steroids
and developed reactivation; while 14 of 72 patients who did not
receive the agent developed the condition (P¼0.017). Out of 41
patients, 19 (46.34%) received anthracyclines and developed
reactivation, while 17 of the 87 (19.54%) patients who had no
anthracyclines developed the condition (P¼0.0029). With respect
to 5-fluorouracil, 61 received the drug, among whom 14 (23%)
developed reactivation, while 22 of 67 patients (33%) who did not
receive the agent developed the condition (P¼0.2419).
On multivariate analysis, the factors that were significantly
associated with a higher risk of developing HBV reactivation were
detectable HBV DNA levels based on real-time PCR measurement
(P¼0.0003, Odds ratio of 8.4 with 95% CI from 2.6 to 27.2), the use
of steroid (P¼0.0465, OR of 2.7 with 95% CI from 1.0 to 7.2), a
diagnosis of lymphoma (P¼0.0419, OR of 5.0 with 95% CI from
1.1 to 23.5) and breast cancer (P¼0.0041, OR of 4.2 with 95% CI
from 1.6 to 11.0).
Predictive model development
A predictive model was determined using the final logistic
regression model, as shown in Table 2. The following is the
Table 1 Characteristics of the 128 HBsAg seropositive cancer patients undergoing cytotoxic chemotherapy
Patients who had hepatitis B viral
reactivation during chemotherapy
Patients who did not develop hepatitis B
viral reactivation during chemotherapy P-value
Total no. of patients 36 92
Sex*
Male 16 (28.6%) 40 (71.4%) 1.0000
Female 20 (27.8%) 52 (72.2%)
Median age (years) 46.5 49 0.2654
Range 30–71 20–78
Tumour type*
Breast cancers 16 (41.0%) 23 (59.0%)
Lymphomas 7 (58.3%) 5 (41.7%)
Gastrointestinal cancers 2 (6.9%) 27 (93.1%) 0.0041
Head and neck cancers 5 (29.4%) 12 (70.6%)
Lung cancers 3 (23.1%) 10 (76.9%)
Other cancers 3 (16.6%) 15 (83.4%)
Pretreatment (baseline) biochemistry
Median ALT levels (normal o58iul
 1) 35 (range: 12–77) 27 (range: 10–96) 0.1025
Median total bilirubin levels (normal
o15mmoll
 1)
7 (range: 2–26) 7 (range: 1–108) 0.9639
Median albumin levels (normal 440gl
 1) 35 (range: 22–43) 36 (range: 20–47) 0.8421
Use of anthracyclines
Yes 19 (46.3%) 22 (53.7%) 0.0029
No 17 (19.5%) 70 (80.5%)
Use of steroids
Yes 22 (39.3%) 34 (61.2%) 0.0174
No 14 (19.4%) 58 (80.6%)
Use of fluorouracil
Yes 14 (23.0%) 47 (77.0%) 0.2419
No 22 (32.8%) 45 (67.2%)
HBeAg status*
Positive 4 (26.7%) 11 (73.3%) 1.0000
Negative 32 (28.3%) 81 (71.7%)
HBV DNA-real-time PCR assay*
Detectable 31 (37.8%) 51 (62.2%) 0.0010
Undetectable 5 (10.9%) 41 (89.1%)
*Fisher’s exact two-sided test.
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lmathematical formula that can be programmed into a personal
computer or programmable calculator:
log
pR
1   pR

¼ b0 þ b1x1 þ b2x2 þ b3x3 þ b4x4
where pR is the probability of HBV reactivation, x1, x2, x3 and x4
are indicator variables for the presence of lymphoma (pre-
sence¼1, absence¼0), breast cancer (presence¼1, absence¼0),
the use of steroids (presence¼1, absence¼0) and HBV virology
load determined by PCR (detectable¼1; not detectable¼0). The
parameters b0, b1, b2, b3, b4 are parameters whose values are given
in Table 2. We would classify a patient to the group with a higher
likelihood of developing HBV reactivation if the estimated pR from
the above logistic model is higher than 0.3. A sensitivity of 75%
and a specificity of 79.3% were obtained based on a cutoff point of
0.3 for the predictive probability of the logistic model. This
optimal predictive probability cutoff point was determined using
the ROC curve method (Figure 1).
DISCUSSION
Hepatitis B virus reactivation during cytotoxic chemotherapy is a
particularly important clinical issue in areas of the world such as
China, where chronic HBV infection is endemic. With the
increasing incidence of neoplastic diseases (Lok et al, 1991), and
the more widespread use of cytotoxic chemotherapy, the
occurrence of HBV reactivation is likely to increase further.
In this study, the identified risk factors included detectable pre-
chemotherapy HBV DNA load (using real-time PCR measure-
ment), the use of steroids, a diagnosis of lymphoma or breast
cancer, another suggested factor being the use of anthracyclines.
Previous studies have reported factors including male sex (Liaw
et al, 1987; Liang et al, 1990; Lok et al, 1991), younger age (Yeo
et al, 2000a), HBeAg positivity (Lok et al, 1991; Yeo et al, 2000a,b)
and the presence of lymphoma (Yeo et al, 2000a). Although the
reason remains unknown, male sex has consistently been reported
to be a risk factor for the exacerbation of chronic HBV infection in
cancer patients undergoing chemotherapy, as well as in non-cancer
subjects (Liaw et al, 1987; Liang et al, 1990; Lok et al, 1991).
Although HBeAg positivity in immunocompromised cancer
patients appears to be a risk factor for HBV reactivation (Liang
et al, 1990; Yeo et al, 2000b), this has not been found to be
universally the case (Lok et al, 1991; Nokamura et al, 1996), and an
increased risk may be partly attributed to the presence of the pre-
core/core promoter HBV mutant (i.e. HBeAg negative/anti-HBe
positive), which had been associated with severe fulminant
hepatitis (Omata et al, 1991; Ehata et al, 1993; Liang et al, 1994;
Nokamura et al, 1996; Steinberg et al, 2000; Yeo et al, 2000a,b). In
addition, consistent with other reports, the baseline (pretreatment)
liver function including ALT, total bilirubin and albumin levels did
not appear to be associated with the development of HBV
reactivation.
Certain limitations are noted in this study. Of the 82 patients
found to have detectable HBV DNA on real-time PCR assay, 67
were HBeAg seronegative, and the existence of precore mutants
was not analysed. In addition, the diagnosis of HBV reactivation
based on HBV DNA measurement upon the development of
hepatitis could be suboptimal in two aspects. First, the commer-
cially available assay (Quantiplex bDNA assay) used was relatively
less sensitive, with a lower detection limit of 0.7 10
6g.e.ml
 1).
Secondly, in the absence of serial monitoring HBV DNA, the true
incidence of viral reactivation might have been underestimated, as
the rise in HBV DNA might have preceded overt hepatitis in some
cases (Yeo et al, 2001).
Several chemotherapeutic agents have been reported to be
associated with the development of HBV reactivation in cancer
patients. Apart from steroids and anthracyclines, other drugs that
have been reported included vincristine, bleomycin, etoposide,
methotrexate, actinomycin D, mercaptopurine, azauridine, chlor-
ambucil, cytosine arabinoside, leucovorin, cisplatin and gemcita-
bine (Galbraith et al, 1975; Hoofnagle et al, 1982; Thung et al, 1985;
Bird et al, 1989; Lau et al, 1989; Liang et al, 1990; Pinto et al, 1990;
Lok et al, 1991; Soh et al, 1992; Nokamura et al, 1996; Wong et al,
1996; Yeo et al, 2000a). In the present study, it is interesting to find
that the use of steroids was an associated risk factor on
multivariate analysis. Patients with lymphoma have more fre-
quently been reported to develop HBV reactivation (Lok et al,
1991; Omata et al, 1991; Nokamura et al, 1996; Yeo et al, 2000a),
and a recent report on breast cancer patients receiving
chemotherapy has shown the viral reactivation rate to be as high
as 41% (Yeo et al, 2003). The type of treatment and the type of
tumour may be inter-related factors. Since disease site confounded
with the use of certain cytotoxic agents, a separate stepwise logistic
regression model without disease site was used for further analysis.
The logistic model without considering the disease site revealed
that anthracyclines (P¼0.0662, OR 2.44, 95% CI from 0.94 to 6.32),
as well as steroids (P¼0.0557, OR 2.56, 95% CI from 0.98 to 6.69)
and detectable HBV DNA (P¼0.0011, OR of 6.25, 95% CI from
2.08 to 18.8) were significant factors. Steroids and anthracyclines
are commonly used as part of the cyclophosphamide/adriamycin/
vincristine/prednisolone (CHOP) regimen for patients with non-
Hodgkin’s lymphoma; they also constitute adriamycin/cyclopho-
sphamide (AC) combination chemotherapy commonly used for
breast cancer patients (where steroid is generally administered in
the anti-emetic pre-medication). Indeed, anthracyclines have
mainly been administered to patients with non-Hodgkin’s
lymphoma and breast cancer (Table 3). Although it is generally
accepted that CHOP is an immunosuppressive regimen, only 4% of
Western breast cancer patients receiving AC developed severe
immunosuppression (Fisher et al, 1990). However, recent data
from Chinese breast cancer patient population revealed the
Table 2 Logistic regression model
95% confidence interval
Parameter P-value
Odds
ratio
Lower Upper
Intercept  3.6589 (b0)
Lymphoma (x1) 1.6086 (b1) 0.0419 5.0 1.06 23.53
Breast (x2) 1.4264 (b2) 0.0041 4.2 1.57 11.02
Steroid (x3) 0.9939 (b3) 0.0465 2.7 1.02 7.19
HBV PCR (x4) 2.1339 (b4) 0.0003 8.4 2.63 27.15
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Figure 1 Logistic model with PCR_HBV, steroid, lymphoma and breast
sites.
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lcorresponding figure to be as high as 77% (Ma et al, 2002). This
implies that the degree of immunosuppression as a result of the
treatment could have been a more significant factor than the type
of malignancy per se in the development of HBV reactivation. This
is further supported by one of the findings from the present study
that revealed that patients with gastrointestinal malignancies, who
undergo cytotoxic chemotherapy mainly consisting of less
immunosuppressive agents (fluorouracil and folinic acid), have a
lower risk of developing viral reactivation. Previous study has
suggested that the type of chemotherapeutic regimens, rather than
the individual cytotoxic agent, may be a more important factor
(Yeo et al, 2000a). Thus, when the use of 5-fluorouracil was
analysed in the present study, no association was found with HBV
reactivation; while the agent was commonly coupled with folinic
acid in gastrointestinal malignancies, it was also often used in
combination with other cytotoxics that resulted in a variable
degree of immunosuppression for non-gastrointestinal malignan-
cies.
Using the real-time PCR assay, which has a lower cutoff value of
2.9 10
3g.e.ml
 1, the present study has revealed that detectable
HBV DNA load prior to chemotherapy was a significant predictive
factor for viral reactivation. Although a recent study has
demonstrated that a detectable HBV DNA may predict HBV
reactivation in HBsAg-positive individuals (Lau et al, 2002), the
finding, which was based on a small heterogeneous group of
patients who underwent autologous hematopoietic cell transplan-
tation, could not be generalised and applied to the majority of
cancer patients who require conventional cytotoxic chemotherapy
without transplantation.
Prophylactic treatment with antiviral nucleotide analogue
lamivudine prior to the start of chemotherapy has been suggested
to be effective in reducing the incidence of HBV reactivation (Rossi
et al, 2001; Liao et al, 2002; Lim et al, 2002; Persico et al, 2002;
Shibolet et al, 2002; Yeo et al, 2002). The use of the proposed
predictive model may aid the identification of high-risk patients
who stand to benefit most from the antiviral, which could in turn
be administered in a most cost-effective manner.
We conclude that, in cancer patients who are positive for HBsAg
and who undergo cytotoxic chemotherapy, high HBV viral load
(42.9 10
3g.e.ml
 1) prior to the administration of cytotoxic
chemotherapy is a significant predictive factor for the development
of HBV reactivation. Other factors that have been identified
include the use of steroids and a diagnosis of lymphoma and breast
cancer. The combination of baseline HBV viral load (using real-
time PCR) and clinical features provide a more sensitive and
specific means of identifying patients who are at risk of developing
HBV reactivation, and who would benefit most from lamivudine
prophylaxis. Although a predictive model has been formed to
identify patients who are at risk of developing HBV reactivation in
this study, there is a need to validate it in a separate cohort of
patients before it can be safely applied in the clinical practice.
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